Immortalized B cells: a neverending source of antigen-presenting cells for vaccines?

References

• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med.137(5), 1142–1162 (1973).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell106(3), 271–274 (2001).
   PubMed Web of Science ®Google Scholar
• Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin. Immunol.13(5), 291–302 (2001).
   PubMed Web of Science ®Google Scholar
• Barratt-Boyes SM, Zimmer MI, Harshyne LA et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J. Immunol.164(5), 2487–2495 (2000).
   PubMed Web of Science ®Google Scholar
• Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat. Biotechnol.18(4), 405–409 (2000).
   PubMed Web of Science ®Google Scholar
• Maus MV, Thomas AK, Leonard DG et al.Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol.20(2), 143–148 (2002).
   PubMed Web of Science ®Google Scholar
• Schultze JL, Michalak S, Seamon MJ et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest.100(11), 2757–2765 (1997).
   PubMed Web of Science ®Google Scholar
• Kondo E, Topp MS, Kiem HP et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J. Immunol.169(4), 2164–2171 (2002).
   PubMed Web of Science ®Google Scholar
• von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood107(7), 2786–2789 (2006).
   PubMed Web of Science ®Google Scholar
• Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell. Res.37, 614–636 (1965).
   PubMed Web of Science ®Google Scholar
• Wiesner M, Zentz C, Mayr C et al. Conditional immortalization of human B cells by CD40 ligation. PLoS ONE3(1), e1464 (2008).
   PubMed Web of Science ®Google Scholar
• Rufer N, Migliaccio M, Antonchuk J et al. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood98(3), 597–603 (2001).
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Tahara H, Ide T, Furuichi Y. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein–Barr virus. Cancer Res.64(10), 3361–3364 (2004).
   PubMed Web of Science ®Google Scholar
• Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol.164(2), 944–953 (2000).
   PubMed Web of Science ®Google Scholar
• Bodnar AG, Ouellette M, Frolkis M et al. Extension of life-span by introduction of telomerase into normal human cells. Science279(5349), 349–352 (1998).
   PubMed Web of Science ®Google Scholar
• Kiyono T, Foster SA, Koop JI et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature396(6706), 84–88 (1998).
   PubMed Web of Science ®Google Scholar
• Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein–Barr virus-transformed human B lymphocytes. J. Virol.68(5), 3410–3414 (1994).
   PubMed Web of Science ®Google Scholar
• Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science251(4989), 70–72 (1991).
   PubMed Web of Science ®Google Scholar
• Arpin C, Dechanet J, Van Kooten C et al. Generation of memory B cells and plasma cells in vitro. Science268(5211), 720–722 (1995).
   PubMed Web of Science ®Google Scholar
• Jung D, Neron S, Lemieux R, Roy A, Richard M. Telomere-independent reduction of human B lymphocyte: proliferation during long-term culture. Immunol. Invest.30(2), 157–168 (2001).
   PubMed Web of Science ®Google Scholar
• Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res.63(11), 2836–2843 (2003).
   PubMed Web of Science ®Google Scholar
• O’Nions J, Allday MJ. Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein–Barr virus or T cell-derived mitogens. J. Gen. Virol.85(Pt 4), 881–895 (2004).
   PubMedGoogle Scholar
• von Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood99(9), 3319–3325 (2002).
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Tsurumi T, Mori N, Kiyono T. Immortalization of Epstein–Barr virus-negative human B lymphocytes with minimal chromosomal instability. Pathol. Int.56(11), 659–667 (2006).
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat. Med.10(5), 475–480 (2004).
   PubMed Web of Science ®Google Scholar
• Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother.53(4), 275–306 (2004).
   PubMed Web of Science ®Google Scholar
• Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood103(6), 2046–2054 (2004).
   PubMed Web of Science ®Google Scholar